Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

Immune checkpoint blockade (ICB) has gained unparalleled success in the treatment of colorectal cancer (CRC). However, undesired side effects, unsatisfactory response rates, tumor metastasis, and drug resistance still hinder the further application of ICB therapy against CRC. Advancing ICB with nano...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zefan, Xiang, Yucheng, Zheng, Yaxian, Kang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630919/
https://www.ncbi.nlm.nih.gov/pubmed/36341334
http://dx.doi.org/10.3389/fimmu.2022.1027124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630919/
https://www.ncbi.nlm.nih.gov/pubmed/36341334
http://dx.doi.org/10.3389/fimmu.2022.1027124

Ejemplares similares